protease-activated cetuximab (CytomX)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameprotease-activated cetuximab (CytomX)

Drug Alias NameEGFR-PDC (CytomX)epidermal growth factor inhibitors (Cytomx Therapeutics)EGFR probody (CytomX)CTX-023-MMAECTX-023

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsAnticancer protein kinase inhibitors

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCytomx Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCytomx Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A